title: Current treatment options for hepatitis C patients co-infected with HIV.
abstract: With the availability of all-oral, direct acting antivirals (DAAs), hepatitis C virus (HCV) therapy has been revolutionized for HIV/HCV co-infected patients. Indeed HCV cure rates are now no longer different between HCV mono and HIV/HCV co-infected persons and are both greater than 95%. Therefore, current treatment guidelines no longer separate these two groups. Indications for HCV treatment and choice of DAA combination are now the same for all HCV patients. In HIV/HCV co-infection however, drug interactions between HIV and HCV agents need be checked prior to starting HCV therapy. Finally, the higher risk of hepatic decompensation in HIV/HCV co-infected patients, including those receiving successful antiretroviral therapy, continues to make these patients a high priority group for receiving access to modern DAA combination therapy.
authors.affiliation: a Department of Medicine I , Bonn University Hospital , Bonn , Germany.|b German Centre for Infection Research (DZIF) , Partner Site Bonn-Cologne , Bonn , Germany.
authors.forename: Jürgen Kurt
authors.initials: JK
authors.lastname: Rockstroh
authors.affiliation: c Whitman-Walker Health , Washington , DC , USA.
authors.forename: W David
authors.initials: WD
authors.lastname: Hardy
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D060085:Coinfection; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006526:Hepatitis C / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D000998:Antiviral Agents
keywords: DAA; HIV; Hepatitis C; antiretroviral therapy; cirrhosis; drug-interaction